FinDogFinDog
Friday, October 30, 2026Closing data · 4:00 PM ET
English
Log in

TECH

Bio-TechneNASDAQ · Life Sciences Tools & Services · Health Care
Previous close
72.66
Change
−0.05 / −0.07%
FinDog View
Neutral
52-Week Range ?
43.20 – 72.75
P/E (TTM) ?
62.8
Forward P/E ?
34.6
Based on consensus earnings for the next 12 months
Market Cap
$11.4B
1M
+0.26%
S&P 500 −0.91% over same period
Volume / Avg Volume
2.6M / 2.9M
0.88× average
Latest earnings analysisFY2026 Q4Reported 2026-08-12

Bio-Techne FY2026: flat $1.22 billion revenue, GAAP EPS up to $1.16

Bio-Techne's fiscal 2026 was a flat year dressed up by prior-year charges: revenue was unchanged at $1.22 billion, GAAP EPS jumped to $1.16, and adjusted EPS inched to $1.93. With the company set to be acquired by Merck KGaA for $73 a share in cash, quarterly operating swings matter far less than deal completion. Read the numbers below as a closing snapshot, not a growth story.

Read the full analysis →
Revenue$1.22BYoY +283.30%
EPS (non-GAAP)$0.52Missest. $0.53
Next-day move−0.08%

Price History

Closing price · USD1M6M1Y5Y
72.372.472.572.672.772.82026-092026-102026-102026-102026-10

Historical P/E

Close ÷ trailing four-quarter EPS · Period median 73.61M6M1Y5Y
60801001202026-042026-062026-082026-092026-10

Recent Earnings

Click to read the FinDog analysis
PeriodReportedRevenueEPS Actual / Est.Next-Day MoveAnalysis

Next Earnings

Date and consensus from the earnings calendar; the analysis is generated automatically after the releaseEarnings Calendar →
Report date
2026-11-03
in 2 days · time TBD
Consensus EPS
$0.45
Last quarter EPS $0.52
Avg. next-day move over the last 6 reports
±2.9%

Decision Panel

Trends · Valuation · Earnings reaction · Guidance credibility — all from company filings and market data
Valuation
P/E is at percentile 47 of its 5-year rangeMid-range
5-year range 40.1 – 132.1 · Median 64.4
Last 4 quarters: $41.7M in buybacks + $49.9M in dividends, 0.80% of market cap combined
P/E (TTM)
62.8
P/B
5.4
P/S
9.4
Dividend Yield
0.50%
Earnings Reaction
Over the last 6 reports, the stock moved ±2.9% on average on the first trading day after, rising 3 times
Most recent −0.08%
Volatility & Correlation
1-year beta 0.14 · Correlation with S&P 500 0.04Low beta
Annualized volatility 45% vs. 12% for the S&P 500
Insider Trading
View all →
Last 90 days · Open-market buys and sells by officers and directors · Amounts in USD millions
No open-market buys or sells by officers or directors in the last 90 days.
Multi-Quarter Financial Trends
View all quarters →
Last 12 quarters · As reported by the company
QuarterRevenue ($B)YoYGross MarginOperating Income ($B)Net Income ($B)Free Cash Flow ($B)EPS
FY2026 Q40.32+1.3%65.8%0.07—0.090.36
FY2026 Q30.31−1.5%66.9%0.080.050.080.32
FY2026 Q20.30−0.4%64.6%0.050.040.080.24
FY2026 Q10.29−1.0%65.6%0.050.040.020.24
FY2025 Q40.32+3.5%62.7%-0.02-0.020.09-0.11
FY2025 Q30.32+4.2%67.9%0.040.020.030.14
FY2025 Q20.30+9.0%65.3%0.050.030.080.22
FY2025 Q10.29+4.5%63.2%0.040.030.050.21
FY2024 Q40.31+1.6%66.4%0.050.040.060.26
FY2024 Q30.30+3.2%67.4%0.070.050.060.31
FY2024 Q20.27+0.4%64.8%0.040.030.070.17
FY2024 Q10.28+2.7%66.9%0.060.050.050.31

Peers

Largest by market cap in the sector · Latest quarterView Health Care sector →
TickerCompanyMarket CapP/ERevenue YoYGross Margin1MView